What Voyager Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 11 |
| Total trades | 0 | 17 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 291,500 |
| Disposed | 0 | 80,209 |
| Net activity | +0 | +211,291 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO | Apr 02 | Sale for tax withholding · S | −11,511 | $3.87 | −$44.5K | 472,549 |
| Shiferman Gregory L. | SVP and General Counsel | Apr 01 | Grant / award · A | +50,000 | — | — | 50,000 |
| Jorgensen Nathan D. | Chief Financial Officer | Feb 24 | Sale for tax withholding · S | −4,668 | $3.77 | −$17.6K | 151,416 |
| Sandrock Alfred | President and CEO | Feb 24 | Sale for tax withholding · S | −14,197 | $3.79 | −$53.8K | 484,060 |
| Swartz Robin | COO & CBO | Feb 24 | Sale for tax withholding · S | −6,458 | $3.77 | −$24.3K | 199,738 |
| Carter Todd Alfred | Chief Scientific Officer | Feb 24 | Sale for tax withholding · S | −4,174 | $3.76 | −$15.7K | 145,718 |
| Sandrock Alfred | President and CEO | Feb 18 | Sale for tax withholding · S | −11,732 | $3.41 | −$40K | 498,257 |
| Swartz Robin | COO & CBO | Feb 18 | Sale for tax withholding · S | −3,882 | $3.44 | −$13.4K | 206,196 |
| Carter Todd Alfred | Chief Scientific Officer | Feb 18 | Sale for tax withholding · S | −3,301 | $3.44 | −$11.4K | 149,892 |
| Sandrock Alfred | President and CEO | Feb 10 | Sale for tax withholding · S | −12,192 | $3.78 | −$46.1K | 509,989 |
| Swartz Robin | COO & CBO | Feb 10 | Sale for tax withholding · S | −4,569 | $3.85 | −$17.6K | 210,078 |
| Carter Todd Alfred | Chief Scientific Officer | Feb 10 | Sale for tax withholding · S | −3,525 | $3.85 | −$13.6K | 153,193 |
| Sandrock Alfred | President and CEO | Feb 06 | Grant / award · A | +86,250 | — | — | 522,181 |
| Jorgensen Nathan D. | Chief Financial Officer | Feb 06 | Grant / award · A | +32,250 | — | — | 156,084 |
| Swartz Robin | COO & CBO | Feb 06 | Grant / award · A | +45,000 | — | — | 214,647 |
| Carter Todd Alfred | Chief Scientific Officer | Feb 06 | Grant / award · A | +33,000 | — | — | 156,718 |
| Ferguson Toby | Chief Medical Officer | Feb 06 | Grant / award · A | +45,000 | — | — | 183,914 |
| Jorgensen Nathan D. | Chief Financial Officer | Oct 03 | Sale for tax withholding · S | −7,666 | $4.78 | −$36.6K | 123,834 |
| Ferguson Toby | Chief Medical Officer | Aug 18 | Open-market sale · S | −19,000 | $3.73 | −$70.9K | 138,914 |
| Sandrock Alfred | President and CEO | Apr 02 | Sale for tax withholding · S | −10,885 | $3.43 | −$37.3K | 430,931 |
Loading...
